• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Global Regulators Forum Accepts China’s Proposal on “Post-Market Clinical Follow-Up Studies” and Seeks Industry Comment

Global Regulators Forum Accepts China’s Proposal on “Post-Market Clinical Follow-Up Studies” and Seeks Industry Comment

Tuesday, 24 November 2020 / Published in Medical Device, News, NMPA Registration in China

Global Regulators Forum Accepts China’s Proposal on “Post-Market Clinical Follow-Up Studies” and Seeks Industry Comment

On October 11, the CMDE (Center for Medical Device Evaluation) of NMPA (National Medical Products Administration) published the Post-Market Clinical Follow-Up Studies for Medical Devices (draft) on the official website of the IMDRF (International Medical Device Regulator Forum).

The proposal document (in English and Chinese) provides guidance in relation to:
– The circumstances where a post-market clinical follow-up (PMCF) study is indicated
– The general principles of PMCF studies involving medical devices
– The design and implementation of PMCF studies
– The use of information from PMCF studies

Although PMCF studies are not intended to replace the premarket data necessary for market authorization, it is one of the several options available in a post-market surveillance program and can contribute to the risk management process.

The acceptance by IMDRF of China’s proposal on PMCF studies is significant, because it shows the growing global leadership and maturity of the Chinese regulator and medical device industry. It is also likely to soon result in updated regulation of PMCF studies in China. Such studies are an important supplement to a manufacturer’s post-market compliance.

IMDRF is a voluntary group formed by regulators from the global medical device industry. The public consultation is currently open for comments until December 11, 2020. Let us know if you would like to send us your comments on the draft, and together we can submit a strong proposal to the CMDE and IMDRF.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: CMDE, IMDRF, PMCF, post-market clinical follow up, post-market surveillance, risk management

What you can read next

china cross border data transfer security assessments
China cross border data transfer security assessments – new measures introduced
New fees, tests and document requirements for DMF registration of APIs
Public Consultation on Chemical Detection and Efficacy Evaluation Methods in Cosmetics

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Clinical trials of sodium hyaluronate complex solution

    Clinical trials of sodium hyaluronate complex solution – draft guidelines issued

    Clinical trials of sodium hyaluronate complex s...
  • China registration of ophthalmic optical measurement devices

    China registration of ophthalmic optical measurement devices – Technical review guidelines issued

    China registration of ophthalmic optical measur...
  • Pre-communication for Hainan medical device clinical RWD

    Pre-communication for Hainan medical device clinical RWD application – Trial measures implemented

    Pre-communication for Hainan medical device cli...
  • Registration platform for cosmetic raw materials safety information

    Registration platform for cosmetic raw materials safety information – Draft guidelines issued

    The registration platform for cosmetic raw mate...
  • Technical guidelines for reporting cosmetics formulas

    Technical guidelines for reporting cosmetics formulas – draft issued

    Technical guidelines for reporting cosmetics fo...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP